Harrison.ai has petitioned the FDA to exempt some radiology AI devices from premarket review, prompting mixed feedback from industry stakeholders.
Key Details
- 1Harrison.ai seeks FDA exemption for certain computer-aided detection (CAD) AI devices from premarket review.
- 2The company argues current US regulatory pathways are too burdensome for rapidly evolving AI.
- 3Stakeholder comments included feedback from RSNA, ACR, and Patient Alliance for Safe Imaging.
- 4ACR emphasized the need to prioritize patient safety and warned against unintended safety risks.
- 5Harrison.ai has 8 FDA clearances covering 12 indications and its products serve over 1,000 facilities in 40 countries.
- 6Consulting firm Rubrum Advising submitted the petition in October 2023.
Why It Matters
If granted, this exemption could significantly alter the regulatory landscape for radiology AI software, balancing innovation access against patient safety concerns. The decision will set a precedent for future AI device oversight in imaging.
Source
Radiology Business
Related News
•Radiology Business
ACR Approves New Framework for Assessing Imaging AI in Practice
The American College of Radiology Council has approved a new practice parameter to guide the assessment and deployment of AI in imaging.
•Radiology Business
Aidoc Raises $150M to Expand Imaging AI Portfolio and Global Reach
Aidoc secures $150M in Series E funding led by Goldman Sachs to accelerate expansion of its clinical AI platform.
•AuntMinnie
AI in Radiology: Augmentation, Not Replacement – Risks and Realities Reviewed
AI is reshaping radiology workflows but is not ready to replace radiologists, as judgment, accountability, and clinical complexity remain unmet by current technology.